Paper Details

  1. Home
  2. Paper Details

An update on new and emerging therapies for relapsing-remitting multiple sclerosis.

Author: Weinstock-GuttmanBianca

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Disease-modifying therapies (DMTs) have been used for over a decade to treat relapsing-remitting multiple sclerosis (RRMS). While first-line DMTs have shown only partial benefits and often have inadequate patient adherence, newer DMTs offer more efficacious treatment, more favorable methods of administration, and lower infusion frequencies, which may improve adherence and clinical outcomes.
Paper Details　
Original Abstract of the Article :
Disease-modifying therapies (DMTs), known to actively reduce relapses and delay disability progression, have been used for the treatment of relapsing-remitting multiple sclerosis (RRMS) for over a decade. These well-known therapies include intramuscular (IM) interferon (IFN) beta-1a (Avonex), subcut...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/24494635

データ提供：米国国立医学図書館（NLM）

New and Emerging Therapies for Relapsing-Remitting Multiple Sclerosis

Multiple sclerosis (MS) is a complex and challenging neurological disorder, like a vast and unforgiving desert landscape. This review provides an update on new and emerging therapies for relapsing-remitting MS (RRMS), highlighting the advancements in treatment strategies over the past decade. It's like exploring new pathways through the desert, searching for more effective ways to combat this challenging condition.

The review discusses the limitations of traditional first-line therapies, such as interferon beta and glatiramer acetate. These treatments are like established oases in the desert, providing some relief but not fully addressing the complexities of the disease. The review also highlights the emergence of new oral DMTs, such as fingolimod, teriflunomide, and dimethyl fumarate, offering potentially more effective and convenient treatment options. These are like discovering new oases with more abundant resources and easier access.

Discovering New Oases: Advances in MS Treatment

The review emphasizes the importance of individualized treatment approaches, tailored to each patient's unique needs. It's like recognizing that each traveler through the desert may have different requirements and preferences. The review also highlights the potential of emerging therapies, such as monoclonal antibodies and other agents, to provide even more effective and targeted treatment options. These are like exploring new territories in the desert, seeking new solutions and innovations.

Navigating the Desert of MS: A Journey of Hope

This review offers a glimmer of hope for individuals living with RRMS. It's like a beacon in the desert, signaling the progress being made in developing new and effective treatments. It reminds us that the journey through the desert of MS is ongoing, with continued research and development leading to new and better options for patients. We must all play our part in supporting research and advocacy efforts to find a cure for MS and improve the lives of those living with this challenging condition.

Dr.Camel's Conclusion

This review provides a comprehensive overview of new and emerging therapies for RRMS, highlighting the advancements in treatment strategies and the potential for future breakthroughs. It underscores the importance of continued research and development to find more effective and individualized treatment options for individuals living with MS. We must continue our journey through the desert of medical knowledge, seeking new oases of hope and healing for those living with this complex and challenging disease.

Date :
  1. Date Completed 2015-04-08
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

24494635

DOI: Digital Object Identifier

85280

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.